Alcresta

IN THE PRESS

Press Releases

Alcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Pancreatitis Patients at Massachusetts General Hospital

April 30, 2025

·

3 min read

Press Releases

Alcresta Therapeutics Announces FDA Expanded Use Clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Pediatric Patients 1 Year of Age and Older

January 16, 2025

·

3 min read

Genetown

Alcresta Therapeutics Announces Commercial Availability of Next-Generation RELiZORB® (iMMOBILIZED LIPASE) Cartridge

May 13, 2024

·

3 min read

Genetown

Alcresta Therapeutics Announces Publication of Cystic Fibrosis Foundation Position Paper Confirming Inline Enzyme Cartridges are Safe and Effective

July 25, 2023

·

2 min read

Drug Development

Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Associated with Reduced Dependence on Parenteral Nutrition

March 16, 2023

·

5 min read

Business

Alcresta Therapeutics Announces Series of Commercial Milestone Achievements for RELiZORB®

April 1, 2022

·

2 min read

Business

Alcresta Therapeutics Announces Appointment of Chris Parrish as Chief Operations Officer

November 29, 2021

·

2 min read

Genetown

Alcresta Therapeutics Announces Medicare Local Coverage Determination that Confirms Coverage for RELiZORB®

September 7, 2021

·

2 min read

Pharm Country

Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB®

June 25, 2019

·

3 min read

Pharm Country

Data from the ASSURE Study of Long-Term Use of RELiZORB® Published in Journal of Pediatric Gastroenterology and Nutrition

August 2, 2018

·

4 min read

AWARDS

JOBS